[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Prokidney Corp (PROK)

Prokidney Corp (PROK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 424,394
  • Shares Outstanding, K 302,060
  • Annual Sales, $ 890 K
  • Annual Income, $ -68,990 K
  • EBIT $ -169 M
  • EBITDA $ -162 M
  • 60-Month Beta 1.66
  • Price/Sales 500.61
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 302.35% (+24.16%)
  • Historical Volatility 57.62%
  • IV Percentile 81%
  • IV Rank 24.38%
  • IV High 966.89% on 01/09/26
  • IV Low 88.15% on 01/07/26
  • Expected Move (DTE 7) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 21
  • Volume Avg (30-Day) 36
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 8,452
  • Open Int (30-Day) 9,088
  • Expected Range 1.4000 to 1.4000

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.13
  • Number of Estimates 3
  • High Estimate $-0.12
  • Low Estimate $-0.15
  • Prior Year $-0.12
  • Growth Rate Est. (year over year) -8.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4000 +0.36%
on 08/13/26
1.7000 -17.35%
on 08/10/26
-0.2050 (-12.73%)
since 07/13/26
3-Month
1.4000 +0.36%
on 08/13/26
2.2400 -37.28%
on 06/30/26
-0.3450 (-19.71%)
since 05/13/26
52-Week
1.4000 +0.36%
on 08/13/26
3.4799 -59.63%
on 10/27/25
-0.9650 (-40.72%)
since 08/13/25

Most Recent Stories

More News
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights

Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027 On...

PROK : 1.4050 (-5.07%)
ProKidney Appoints Kenneth Locke as Chief Technical Officer

WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney...

PROK : 1.4050 (-5.07%)
ProKidney's Loss Narrative Continues, But the Timing of Profitability Remains Anyone's Guess

Barchart Research What to Expect from PROK Earnings PROK Generated May 15, 2026 Current Price $1.6600 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 6.69% ProKidney's Loss Narrative Continues,...

PROK : 1.4050 (-5.07%)
ProKidney's Loss Narrative Continues, But the Timing of Profitability Remains Anyone's Guess

Barchart Research What to Expect from PROK Earnings PROK Generated May 15, 2026 Current Price $1.6600 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 6.69% ProKidney's Loss Narrative Continues,...

PROK : 1.4050 (-5.07%)
ProKidney's Loss Narrative Continues, But the Timing of Profitability Remains Anyone's Guess

Barchart Research What to Expect from PROK Earnings PROK Generated May 15, 2026 Current Price $1.6600 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 6.69% ProKidney's Loss Narrative Continues,...

PROK : 1.4050 (-5.07%)
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 Peer-reviewed results from the Phase...

PROK : 1.4050 (-5.07%)
ProKidney's Earnings Call Will Test Whether Biotech Investors Still Believe in Kidney Regeneration

Barchart Research What to Expect from PROK Earnings PROK Generated May 8, 2026 Current Price $1.8600 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 6.69% ProKidney's Earnings Call Will...

PROK : 1.4050 (-5.07%)
ProKidney's Earnings Call Will Test Whether Biotech Investors Still Believe in Kidney Regeneration

Barchart Research What to Expect from PROK Earnings PROK Generated May 8, 2026 Current Price $1.8600 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 6.69% ProKidney's Earnings Call Will...

PROK : 1.4050 (-5.07%)
ProKidney's Earnings Call Will Test Whether Biotech Investors Still Believe in Kidney Regeneration

Barchart Research What to Expect from PROK Earnings PROK Generated May 8, 2026 Current Price $1.8600 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 6.69% ProKidney's Earnings Call Will...

PROK : 1.4050 (-5.07%)
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney...

PROK : 1.4050 (-5.07%)

Business Summary

ProKidney LP is a late clinical-stage cellular therapeutics company focused on CKD. The company's lead product candidate includes REACT(TM) is a first-of-its-kind, patented disease-modifying autologous cellular therapy. ProKidney LP, formerly known as Suvretta Holdings Corp. III, is based in WINSTON-SALEM,...

See More

Key Turning Points

3rd Resistance Point 1.5867
2nd Resistance Point 1.5483
1st Resistance Point 1.4767
Last Price 1.4050
1st Support Level 1.3667
2nd Support Level 1.3283
3rd Support Level 1.2567

See More

52-Week High 3.4799
Fibonacci 61.8% 2.6854
Fibonacci 50% 2.4399
Fibonacci 38.2% 2.1945
Last Price 1.4050
52-Week Low 1.4000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.